Rupee rises one paisa to close at 83.96 against U.S. dollar
The Hindu
Rupee edges higher against dollar as RBI maintains rates, with focus on geopolitical tensions and market trends.
The Rupee traded in a narrow range and settled for the day higher by just one paisa at 83.96 (provisional) against the U.S. dollar on Wednesday (October 9, 2024), after the Reserve Bank of India (RBI) kept its key interest rate unchanged and shifted its stance to 'neutral' that may lead to a cut in benchmark rates in forthcoming policies.
Forex traders said the Reserve Bank's monetary policy action was in line with street expectations. Moreover, a muted trend in domestic markets and positive U.S. dollar weighed on investor sentiments.
At the interbank foreign exchange market, the local unit opened at 83.92 and finally settled for the day at 83.96 (provisional), higher by one paisa over its previous close of 83.97 against the dollar.
The Reserve Bank of India on Wednesday (October 9, 2024) kept the policy rate unchanged for the tenth time in a row but shifted its stance from 'withdrawal of accommodation' to 'neutral' that may lead to a cut in the forthcoming policies.
The monetary policy committee, which included three RBI officials and an equal number of new external members, voted five-to-one to keep the benchmark repurchase or repo rate — which governs the interest rate of home, auto, corporate and other loans — at 6.5% for a 10th straight policy meeting.
“The Indian Rupee remained steady as the Reserve Bank of India (RBI) left repo rate and CRR unchanged at 6.5% and 4.5%, respectively, in line with street expectations,” said Anuj Choudhary – Research Analyst at Sharekhan by BNP Paribas.
"We expect the Rupee to trade with a negative bias on selling pressure from FIIs and geopolitical tensions in the Middle East. A strong U.S. dollar may further pressurise the Rupee.
Rupee hits all-time low at 85.20 against USD due to strong greenback, rising crude oil prices, and weak domestic markets.
Viatris faces U.S. FDA import alert for products from Indore plant, exceptions made for certain shortages.
xAI’s Grok may soon come to an iOS app as the company announced its Series C funding round of $6 billion.
Biocon and Zentiva receive EU approval for Liraglutide, a complex formulation for diabetes and weight management.
Equity markets fluctuate as Sensex and Nifty rise initially, then fall; global markets and oil prices also discussed.
Microsoft has been working on adding internal and third-party AI models to power Microsoft 365 Copilot.
China's dominance in critical minerals poses supply chain vulnerabilities for India, US, and EU nations, requiring strategic diversification efforts.
India's controversial popcorn tax system sparks outrage and criticism, with opposition questioning the complex GST rates.
ICAI President investigates auditing lapses at Byju's, disciplinary committee probing, details undisclosed, part of ongoing investigations.
Sensex and Nifty rebound sharply after steep decline, driven by value buying, bluechip stocks, and global market rally.
AS-IT-IS Nutrition aims for ₹300 crore GMV in 2025 with ATOM range, endorsed by Ravindra Jadeja.